
Cannabinoid Agonist - Pipeline Insight, 2025
Description
DelveInsight’s, “Cannabinoid Agonist - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Cannabinoid Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cannabinoid Agonist: Overview
Cannabinoid agonists are compounds that activate the cannabinoid receptors (CB1 and CB2), which are part of the endocannabinoid system. These agonists can be natural (e.g., tetrahydrocannabinol or THC from cannabis), endogenous (e.g., anandamide), or synthetic (e.g., nabilone). They have diverse therapeutic applications, including pain management, appetite stimulation, anti-inflammatory effects, and neuroprotection. The increasing incidence of chronic pain, cancer, epilepsy, and neurodegenerative diseases has driven the demand for novel therapeutics, including cannabinoid agonists.
Cannabinoid agonists are compounds that activate cannabinoid receptors (CB1 and CB2) in the endocannabinoid system. Their structures typically feature terpene and phenolic components, which are characteristic of both phytocannabinoids (like THC and CBD) and synthetic cannabinoids (like dronabinol). Endogenous agonists, such as anandamide, have a fatty acid backbone with an amide group and long carbon chains. Phytocannabinoids, like THC, have a benzopyran ring fused with a terpene structure, while synthetic cannabinoids often include modified aromatic rings, providing unique receptor-binding properties. These structural features determine their ability to bind and activate cannabinoid receptors, influencing various physiological processes.
Cannabinoid agonists interact with the CB1 and CB2 receptors:
Cannabinoid agonists have diverse therapeutic applications due to their interaction with the endocannabinoid system. They are widely used in pain management, particularly for chronic and neuropathic pain, and have shown efficacy in reducing inflammation in autoimmune diseases like rheumatoid arthritis. In neurological disorders, they help manage symptoms of epilepsy, multiple sclerosis, and Parkinson’s disease. For mental health, they offer potential in treating anxiety, depression, and PTSD. In oncology, they assist with chemotherapy-induced nausea and vomiting and stimulate appetite in cancer and HIV/AIDS patients. Additionally, their neuroprotective properties are being explored for Alzheimer’s disease and other neurodegenerative conditions.
“Cannabinoid Agonist - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cannabinoid Agonist pipeline landscape is provided which includes the disease overview and Cannabinoid Agonist treatment guidelines. The assessment part of the report embraces, in depth Cannabinoid Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cannabinoid Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cannabinoid Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cannabinoid Agonist Emerging Drugs
Alzheimer's disease.
Further product details are provided in the report……..
Cannabinoid Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Cannabinoid Agonist drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Cannabinoid Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabinoid Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabinoid Agonist drugs.
Cannabinoid Agonist Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Cannabinoid Agonist: Overview
Cannabinoid agonists are compounds that activate the cannabinoid receptors (CB1 and CB2), which are part of the endocannabinoid system. These agonists can be natural (e.g., tetrahydrocannabinol or THC from cannabis), endogenous (e.g., anandamide), or synthetic (e.g., nabilone). They have diverse therapeutic applications, including pain management, appetite stimulation, anti-inflammatory effects, and neuroprotection. The increasing incidence of chronic pain, cancer, epilepsy, and neurodegenerative diseases has driven the demand for novel therapeutics, including cannabinoid agonists.
Cannabinoid agonists are compounds that activate cannabinoid receptors (CB1 and CB2) in the endocannabinoid system. Their structures typically feature terpene and phenolic components, which are characteristic of both phytocannabinoids (like THC and CBD) and synthetic cannabinoids (like dronabinol). Endogenous agonists, such as anandamide, have a fatty acid backbone with an amide group and long carbon chains. Phytocannabinoids, like THC, have a benzopyran ring fused with a terpene structure, while synthetic cannabinoids often include modified aromatic rings, providing unique receptor-binding properties. These structural features determine their ability to bind and activate cannabinoid receptors, influencing various physiological processes.
Cannabinoid agonists interact with the CB1 and CB2 receptors:
- CB1 Receptors: Primarily located in the brain and central nervous system, influencing mood, memory, pain perception, and appetite.
- CB2 Receptors: Found in immune cells and peripheral tissues, playing a role in inflammation and immune modulation.
Cannabinoid agonists have diverse therapeutic applications due to their interaction with the endocannabinoid system. They are widely used in pain management, particularly for chronic and neuropathic pain, and have shown efficacy in reducing inflammation in autoimmune diseases like rheumatoid arthritis. In neurological disorders, they help manage symptoms of epilepsy, multiple sclerosis, and Parkinson’s disease. For mental health, they offer potential in treating anxiety, depression, and PTSD. In oncology, they assist with chemotherapy-induced nausea and vomiting and stimulate appetite in cancer and HIV/AIDS patients. Additionally, their neuroprotective properties are being explored for Alzheimer’s disease and other neurodegenerative conditions.
“Cannabinoid Agonist - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cannabinoid Agonist pipeline landscape is provided which includes the disease overview and Cannabinoid Agonist treatment guidelines. The assessment part of the report embraces, in depth Cannabinoid Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cannabinoid Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cannabinoid Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Cannabinoid Agonist.
This segment of the Cannabinoid Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cannabinoid Agonist Emerging Drugs
- AP-707: Apurano Pharmaceuticals
- IGC-AD1: IGC Pharma, INC
- NTRX 07: NeuroTherapia
Alzheimer's disease.
Further product details are provided in the report……..
Cannabinoid Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Cannabinoid Agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cannabinoid Agonist
Phases
DelveInsight’s report covers around 22+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Cannabinoid Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabinoid Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabinoid Agonist drugs.
Cannabinoid Agonist Report Insights
- Cannabinoid Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cannabinoid Agonist drugs?
- How many Cannabinoid Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cannabinoid Agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cannabinoid Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cannabinoid Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Apurano Pharmaceuticals
- IGC Pharma, Inc
- Artelo Biosciences, Inc
- NeuroTherapia
- Oxford Cannabinoid Technologies Holdings
- SciSparc
- Mira Pharmaceuticals
- InMed Pharmaceuticals
- Corbus Pharmaceuticals
- AP-707
- IGC-AD1
- ART27.13
- NTRX 07
- OCT461201
- SCI 160
- MIRA-55
- INM 901
- CRB 913
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Cannabinoid Agonist : Overview
- Introduction
- Structure
- Function
- Mechanism of action
- Therapeutic Applications
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- Cannabinoid Agonist – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- AP-707: Apurano Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- IGC-AD1: IGC Pharma, INC
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- NTRX 07: NeuroTherapia
- Product Description
- Research and Development
- Product Development Activities
- Preclinical Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cannabinoid Agonist-Collaborations Assessment- Licensing / Partnering / Funding
- Cannabinoid Agonist- Unmet Needs
- Cannabinoid Agonist- Market Drivers and Barriers
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.